KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Gross Profit (2016 - 2025)

Emergent BioSolutions (EBS) has 15 years of Gross Profit data on record, last reported at $63.8 million in Q4 2025.

  • For Q4 2025, Gross Profit fell 16.82% year-over-year to $63.8 million; the TTM value through Dec 2025 reached $416.7 million, up 3.22%, while the annual FY2025 figure was $416.7 million, 15.02% up from the prior year.
  • Gross Profit reached $63.8 million in Q4 2025 per EBS's latest filing, down from $145.2 million in the prior quarter.
  • Across five years, Gross Profit topped out at $376.8 million in Q1 2021 and bottomed at $11.4 million in Q1 2023.
  • Average Gross Profit over 5 years is $168.4 million, with a median of $147.3 million recorded in 2023.
  • Peak YoY movement for Gross Profit: tumbled 94.92% in 2023, then skyrocketed 1266.67% in 2024.
  • A 5-year view of Gross Profit shows it stood at $292.4 million in 2021, then increased by 8.93% to $318.5 million in 2022, then plummeted by 71.27% to $91.5 million in 2023, then dropped by 16.17% to $76.7 million in 2024, then dropped by 16.82% to $63.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $63.8 million in Q4 2025, $145.2 million in Q3 2025, and $74.0 million in Q2 2025.